Harvard and Merck will collaborate on research led by Harvard immunologist Arlene Sharpe seeking to identify new pathways for the treatment of cancer. Under the terms of the agreement with Harvard’s Office of Technology Development, Merck will have the option to negotiate an exclusive license to innovations arising from the research collaboration to develop discoveries toward potential treatments for patients.
Harvard and Merck will launch a collaboration that offers significant research funding for up to four years to support immune-oncology research led by Dr. Arlene Sharpe, MD, Ph.D., at Harvard Medical School. Sharp will collaborate with Merck researchers on a major project aiming to discover novel aspects of the immune system that may be targeted in future cancer treatments.
The funding supports the work of scientists at the lab of Dr. Sharpe, who is a renowned leader in the field of tumor immunology. She is a member of the National Academy of Sciences and the National Academy of Medicine, and the recipient of numerous awards including the Warren Alpert Foundation Prize 2017 for her contributions to the discovery of the PD-1 pathway.
Dr. Arlene Sharpe, MD, Ph.D., at Harvard Medical School